Table 1 Demographic and clinical characteristics
From: Increased circulating Tfh to Tfr ratio in chronic renal allograft dysfunction: a pilot study
CAD group | Stable group | P-value | |
|---|---|---|---|
N = 34 | N = 33 | ||
Age (range), years | 44 (22–53) | 41 (26–53) | 0.213 |
Male, percentage | 28, 82% | 24, 73% | 0.352 |
Pre-PRA (range), % | 0 (0–24.1) | 0 (0–26.8) | 0.111 |
HLA mismatch (range) | 4 (2–7) | 4 (0–6) | 0.164 |
Transplant Duration (range), months | 55 (6–132) | 36 (6–108) | 0.089 |
Immunosuppressant | 0.045 | ||
--Tacrolimus | --21 | --27 | |
--Sirolimus | --7 | --5 | |
--Cyclosporine A | --1 | --1 | |
--CNI + Sirolimus | --5 | --0 | |
eGFR (range), ml/min/1.73m2 | 33.2 (4.8–58.9) | 74.1 (60.9–121.6) | < 0.001 |